ACELYRIN Inc

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Acelyrin Inc reports strong Q2 results, optimistic on transformative medicines

Acelyrin Inc showcased positive trial data for izokibep in HS and PsA, emphasizing transformative medicines
Company's strong financial position post-IPO and detailed responses on key program benefits
Analyst questions highlighted focus on trial timelines, differentiation, and dosing strategies
Overall positive outlook on pipeline and commitment to delivering innovative medicines

Acelyrin reports strong Q2 results, focuses on lonigutamab progress

Acelyrin Inc (SLRN) showcased positive performance in key drug programs and financial sustainability measures during Q2 2024.
While facing challenges such as workforce reductions and tinnitus cases, the company remains well-positioned for growth and clinical advancement.
Opportunities lie in engaging with regulators, sharing program updates, and leveraging their cash position for strategic expansion.
Investors can expect continued progress and transparency from Acelyrin as they navigate clinical milestones and investor engagements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

The IPO price will remain between $16 and $18 a share, Acelyrin said in a filing with the Securities and Exchange Commission on Wednesday.

Acelyrin boosts IPO size, maintains expected price range

Acelyrin, Inc. has filed proposed terms for a $350 million U.S. IPO. The firm is developing treatment candidates for a variety of inflammatory diseases.

IPO Update: Acelyrin Readies $350 Million U.S. IPO

BKV Corp

Fidelis Insurance Holdings Ltd

Hanryu Holdings Inc

Jayud Global Logistics Ltd

Kenvue

Top Kingwin Ltd

Trio Petroleum Corp

Interactive Strength Inc

U Power Ltd

US Goldmining Inc

Wang & Lee Group Inc

U.S. IPO Weekly Recap: IPO Market Has A Full Week Of Small Deals, Led By Chinese Issuers.

U.S. IPO Weekly Recap: IPO Market Has A Full Week Of Small Deals, Led By Chinese Issuers

ACELYRIN, Inc. has filed to raise development funding via a U.S. IPO. The firm is a clinical-stage biopharma developing treatments for various inflammatory diseases.

Acelyrin Begins Rollout Of U.S. IPO Plan

News for ACELYRIN Inc Stock (SLRN)